Fludarabine
Relapsed / Refractory Solid Tumor
Tianjin Medical University Cancer Institute and HospitalSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Relapsed / Refractory Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Anti-Cd70-Car-T Cells Tianjin Medical University Cancer Institute and Hospital | Phase 1 | CC |
cht101 Tianjin Medical University Cancer Institute and Hospital | Phase 1 | CC |
Cyclophosphamide Tianjin Medical University Cancer Institute and Hospital | Phase 1 | CC |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →